CryoPortCYRX
CYRX
About: CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Employees: 1,170
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
3,011% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $71K
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
28% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 46
6% more funds holding
Funds holding: 151 [Q3] → 160 (+9) [Q4]
1.08% more ownership
Funds ownership: 94.64% [Q3] → 95.72% (+1.08%) [Q4]
3% less capital invested
Capital invested by funds: $379M [Q3] → $368M (-$10.7M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
130%
upside
Avg. target
$11
130%
upside
High target
$11
130%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham David Saxon 43% 1-year accuracy 29 / 67 met price target | 130%upside $11 | Buy Reiterated | 17 Jan 2025 |
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
NASHVILLE, Tenn. , Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for January 29th
MC, LFST, EAT, CYRX and HCP have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2024.
Neutral
PRNewsWire
1 month ago
Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies
New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today unveiled its Cryoport Express® Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings.
Neutral
PRNewsWire
1 month ago
Moffitt Cancer Center and Cryoport Announce Strategic Collaboration
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn.
Neutral
PRNewsWire
1 month ago
Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")
All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cryoport company and the leading global manufacturer of high-quality cryogenic freezers and dewars, has officially registered all three of its manufacturing facilities (located in Ball Ground, Georgia; New Prague, Minnesota; and Chengdu, China) with the U.S. Food and Drug Administration ("FDA").
Negative
Seeking Alpha
3 months ago
Cryoport Remains A Disappointing Prospect
Cryoport operates in the promising life sciences sector but continues to suffer from poor fundamentals and significant cash flow challenges. Despite slight revenue growth in Q3 2024, the company remains unprofitable and has seen a drastic share price decline since my initial 'sell' rating. Recent financial improvements are minimal, with net losses narrowing and cash flow turning slightly positive, but the overall outlook remains bleak.
Neutral
PRNewsWire
3 months ago
Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening of its newest IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium.
Neutral
Seeking Alpha
3 months ago
Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP Investor Relations and Corporate Development Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Puneet Souda - Leerink Partners Operator Good afternoon and welcome to the Cryoport Second Quarter 2024 Earnings Call. All participants will start in a listen-only mode.
Negative
Zacks Investment Research
3 months ago
CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.31 per share a year ago.
Neutral
PRNewsWire
3 months ago
Cryoport Reports Third Quarter 2024 Financial Results
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024.
Charts implemented using Lightweight Charts™